Core Insights - Medtronic exceeded Wall Street profit expectations for Q3, driven by strong demand for heart devices and diabetes monitors [1] - The company maintained its fiscal 2026 adjusted profit forecast at $5.62 to $5.66 per share [1] - Medtronic's cardiovascular segment, accounting for nearly 40% of sales, saw a 13.8% increase in sales to $3.46 billion [1] Financial Performance - Total revenue for Q3 was $9.02 billion, surpassing estimates of $8.91 billion [1] - Adjusted quarterly profit was reported at $1.36 per share, beating analysts' average estimate of $1.33 per share [1] Market Dynamics - The medtech industry is experiencing increased demand for medical procedures, as indicated by higher medical loss ratios reported by health insurers [1] - Technological advancements and wider physician adoption are contributing to market optimism [1] - Medtronic's growth is supported by its pulsed field ablation systems and transcatheter aortic valve replacement devices, which are rapidly gaining traction [1]